De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

NCT05541016 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

455

Enrollment

OTHER

Sponsor class

Conditions

Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Cisplatin
PROCEDURE: Computed Tomography
RADIATION: Diffusing Alpha-emitter Radiation Therapy
DRUG: Docetaxel
PROCEDURE: Intensity-Modulated Proton Therapy
RADIATION: Intensity-Modulated Radiation Therapy
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Modified Barium Swallow Study
OTHER: Observation Activity
PROCEDURE: Positron Emission Tomography
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire

Sponsor

Mayo Clinic